SUBSCRIBE
SUBSCRIBE
News   Business

Q2 2011: BioAlliance Pharma Accelerates the Progress of Its “Orphan Oncology Products” Portfolio and Pursues Its International Partnerships on Its “Specialty Products”

July 28, 2011 | 
1 min read
PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO)(Euronext Paris - BIO), a company dedicated to specialty and orphan oncology products, today reported a consolidated turnover of €576,000 for the second quarter of 2011.
Earnings Europe
MORE ON THIS TOPIC
Rheumatoid arthritis (RA) commonly causes inflammation in the hands, leading to pain, swelling, and stiffness in the joints, particularly the small joints of the fingers and wrists. This inflammation results from the immune system attacking the body's own joint tissues, causing the synovium (lining of the joint) to become inflamed and release chemicals that damage nearby tissues.
Mergers & acquisitions
Sobi Makes $1.5B Gout Play With Arthrosi Acquisition
December 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Pfizer, Geron Downsize To Streamline Costs
December 12, 2025
 · 
95 min read
 · 
BioSpace Editorial Staff
Creative collage illustration of financial business. Two businessmen shaking hands for partners agreement. Conceptual illustration of success deal, corporate ethic, connection.
Weight loss
Zealand Bets up to $2.5B in Metabolic Pact With Chinese Biotech
December 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Pfizer's signage outside its office in Canada/iStock, JHVEPhoto
Layoffs
Pfizer’s Cost Cuts Claim 200+ Jobs in Switzerland: Report
December 11, 2025
 · 
2 min read
 · 
Tristan Manalac